Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024

Rhea-AI Summary

Cerus (Nasdaq: CERS) has announced that it will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the stock market closes. The company will host a conference call and webcast at 4:30 P.M. ET on the same day to discuss the financial results and provide a general business overview and outlook.

Interested parties can access the live webcast and presentation slides on the Investor Relations page of Cerus' website. Participants are encouraged to register for the call and join 10 minutes before the event starts. A replay of the call will be available on Cerus' website approximately three hours after the call and will remain accessible until August 22, 2024.

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event.

A replay will be available on Cerus’ website and will be available approximately three hours after the call through August 22, 2024.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240718327855/en/

Jessica Hanover – Vice President, Corporate Affairs

Cerus Corporation

925-288-6137

Source: Cerus Corporation

FAQ

When will Cerus (CERS) release its Q2 2024 financial results?

Cerus (CERS) will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the stock market closes.

What time is Cerus 's (CERS) Q2 2024 earnings call scheduled for?

Cerus 's (CERS) Q2 2024 earnings conference call and webcast is scheduled for 4:30 P.M. ET on Thursday, August 1, 2024.

Where can I access Cerus 's (CERS) Q2 2024 earnings webcast?

You can access Cerus 's (CERS) Q2 2024 earnings webcast on the Investor Relations page of the company's website at http://ir.cerus.com.

Until when will the replay of Cerus 's (CERS) Q2 2024 earnings call be available?

The replay of Cerus 's (CERS) Q2 2024 earnings call will be available on the company's website until August 22, 2024.